Xtant Medical Holdings, Inc. (NYSE American: XTNT) reported its financial results for the third quarter of 2026 and announced a board-led strategic review process. The company reported total revenue of $24.3 million for the third quarter of 2026, a decrease from $33.3 million in the prior year's third quarter but an increase of 5% from the second quarter of 2026. The year-over-year decline was primarily attributed to the absence of revenue from divested non-core assets and wound care licensing revenue, partially offset by $2.2 million in sales of HEMOBLAST Bellows.

Biologics revenue for the quarter was $19.3 million, representing an 11% increase from the second quarter of 2026 and a 13% increase from the third quarter of 2025. However, the company reported a net loss of $3.6 million, or $0.03 per share, compared to net income of $1.3 million in the prior year. Gross margin for the third quarter of 2026 was 56.3%, down from 66.1% in the same period of 2025, driven by the cessation of high-margin wound care licensing revenue and changes in sales mix.

Regarding its financial position, Xtant Medical held $7.8 million in cash and cash equivalents as of September 30, 2026. The company had $22 million in total indebtedness, consisting of $10.2 million in current and long-term debt and $11.8 million in revolving credit facility borrowings, leaving $2.1 million of availability under the facility. The company stated that its current cash and availability are sufficient to fund operations for at least the next 12 months.

Chairman of the Board Stavros Vizirgianakis expressed disappointment with the financial performance, noting it was the second consecutive quarter results did not meet guidance. In response, the Board has initiated a comprehensive review of strategic, operational, and financial alternatives to maximize stockholder value. These potential actions may include operational improvements, capital allocation changes, partnerships, restructurings, or other transactions. The Board has not set a timetable for the review and will not disclose further developments until a specific action is approved. Additionally, the company confirmed it no longer expects to achieve its previously issued full-year 2026 guidance.